CBL
DEAD

Serial Number

85390442

Owner

CHANTILLY BIOPHARMA

Attorney

CRAIG M. BELL

First Use Date

Mar 20, 2011

Filing Date

Aug 5, 2011

Add to watchlist:

No watchlists yet
View on USPTO

CBL Trademark

Serial Number: 85390442 • Registration: 4333516

CBL is a trademark filed by CHANTILLY BIOPHARMA on August 5, 2011. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

CHANTILLY BIOPHARMA (3 trademarks)

3701 CONCORDE PARKWAY
CHANTILLY, VA 20151

Entity Type: 03

Trademark Details

Filing Date

August 5, 2011

Registration Date

May 14, 2013

First Use Anywhere

March 20, 2011

First Use in Commerce

March 20, 2011

Published for Opposition

February 26, 2013

Cancellation Date

December 20, 2019

Goods & Services

Analgesic and muscle relaxant pharmaceutical preparations; Anti-diabetic pharmaceuticals; Antibacterial pharmaceuticals; Cardiovascular pharmaceuticals; Cellulose esters for pharmaceutical purposes; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of a coating for tablets that facilitate the delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical preparation for skin care; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations, namely, appetite suppressants; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceuticals, namely, lipid lowering agents

Active chemical ingredients and excipients for use in the manufacture of pharmaceuticals consisting of compounds that facilitate delivery of a wide range of pharmaceuticals for pharmaceutical actives

Filing History

CANCELLED SEC. 8 (6-YR)
Dec 20, 2019 C8..
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
May 14, 2018 REM1
REGISTERED-PRINCIPAL REGISTER
May 14, 2013 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 26, 2013 NPUB
PUBLISHED FOR OPPOSITION
Feb 26, 2013 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 6, 2013 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jan 23, 2013 PREV
ASSIGNED TO LIE
Jan 23, 2013 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 8, 2013 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 11, 2012 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 11, 2012 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 11, 2012 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 13, 2012 GNRN
NON-FINAL ACTION E-MAILED
Aug 13, 2012 GNRT
NON-FINAL ACTION WRITTEN
Aug 13, 2012 CNRT
ASSIGNED TO EXAMINER
Jul 3, 2012 DOCK
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 6, 2012 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 5, 2012 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 5, 2012 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 12, 2011 GNRN
NON-FINAL ACTION E-MAILED
Dec 12, 2011 GNRT
NON-FINAL ACTION WRITTEN
Dec 12, 2011 CNRT
ASSIGNED TO EXAMINER
Nov 30, 2011 DOCK
NOTICE OF PSEUDO MARK MAILED
Aug 11, 2011 MPMK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 10, 2011 NWOS
NEW APPLICATION ENTERED
Aug 9, 2011 NWAP